The CPD event takes place this Thursday 9th April, from 9:30am to 5:30pm, using the Zoom video conferencing platform. The organisers say that the agenda is still being finalised, but will be split into three streams: Farm Animal, Equine and Small Animal.
Confirmed speakers include:
Although the event is free, participants are asked make a voluntary contribution at justgiving.com/fundrasing/vets-for-nhs.
To register for the event, visit www.vetsfornhs.co.uk
Vets for NHS is supported by Boehringer Ingelheim, MSD Animal Health, Nimrod and the Scottish Vet Fair.
In contrast to the British Veterinary Association, The National Office of Animal Health (NOAH) has welcomed the decision by DEFRA not to proceed with the proposal contained in the draft Veterinary Medicines Regulations 2010 to prohibit the advertising of antimicrobials to farmers.
NOAH says it believes the proposal would have had a negative effect on farmers' ability to maintain their knowledge and awareness of animal health and welfare issues, and did not believe that it would reduce antimicrobial resistance profiles.
NOAH chief executive Phil Sketchley said: "Farmers, as professional producers of food, need to be kept well briefed on the antimicrobials they use, following prescription by their veterinary surgeons. Promotion by our members plays a key role in this and in educating farmers about animal welfare and disease."
NOAH members follow rigid rules on advertising and promotion through the longstanding Code of Practice for the Promotion of Animal Medicines.
Phil added: "The NOAH Code already goes beyond the Veterinary Medicines Regulations and is reviewed each year - this year we will be particularly looking to ensure that it fully reflects the industry's commitment to disease education and information on responsible use, particularly in relation to antimicrobial promotion. We have planned, at our Code review meeting in February, further discussions within NOAH and with the VMD to finalise how this can best be achieved.
"Importantly we must always remember that antimicrobial medicines for all animals are POM-V, meaning they have to be prescribed by a veterinary surgeon, and therefore it should be the vet who makes the decision on whether an antibiotic is needed. If such therapy is indicated, the most appropriate antibiotic for an animal or group of animals is selected by the veterinary surgeon based on the clinical signs shown, the current disease situation on the farm and in the area and where appropriate and feasible, is based on bacterial culture and sensitivity testing."
Using promotion to encourage responsible use, NOAH launched its 'Use Medicines Responsibly' campaign in 2009. A recommendation was made that members include a strap line on promotional material advising users to 'use medicines responsibly'.
NOAH was a founder member of the Responsible Use of Medicines in Agriculture Alliance (RUMA) and continues to be a strong contributor to and supporter of RUMA's communications to farmers including the antimicrobial guidelines. These guidelines are not intended to influence the veterinary surgeon's decision to prescribe but help support ways that the veterinary surgeon and farmer can work together to reduce the need to prescribe antimicrobials whilst ensuring they are used responsibly once prescribed in line with the principle of 'as little as possible but as much as necessary'.
Phil said: "Antibiotics are essential for the health and welfare of the UK's livestock population. NOAH accepts that antimicrobial resistance is a serious and growing subject of discussion for the medical and veterinary professions and we need to continue to take this matter seriously."
The company highlights figures which show that about 170,000 of calves born alive each year die in their first month of life1 and that up to 50% of deaths are caused by scour2, with over 48% of dairy heifer calves diagnosed with scour preweaning3. ORT, says the company, could help save the industry £60 million a year1.
The new campaign will encourage farmers to use ORT during scouring to provide sufficient essential electrolytes to correct acidosis, while still continuing with milk feeding. The company says milk is the best source of energy and fluid replacement for scouring calves and stopping milk has been shown to have no impact on the resolution of scour. In fact, calves left on milk during scour can continue to gain weight. The Making Milk Matter Against Scour initiative is being backed by a PR and advertising campaign and a social media initiative.
During the campaign Ceva will be running surveys to capture both vets’ and farmers’ experiences of scour and ORT. To take part in the vet survey visit https://www.surveymonkey.co.uk/r/ORTVet. There will be a prize draw from completed entries, with 10 vets receiving a £10 Amazon voucher.
Stephenie Clarke, product manager at Ceva Animal Health said: "The ‘Making Milk Matter Against Scour’ campaign will help highlight the financial and welfare benefits of using ORT at the first signs of scour and the importance of administering it alongside milk which is the best source of energy and will help calves maintain weight gain.
"The scour survey will provide us with an insight into the use of ORT in practice and on farm to help us drive improvements across the industry."
James Adams, BVSc FHEA MRCVS, farm animal lead at Langford Vets, University of Bristol, added: “If I could offer one piece of advice to farmers with scouring animals it would be to ensure hydration as dehydration is what kills! Rehydrating an animal is essential if an animal is to be able to regain its normal function and fend off any disease.
"We’ve been using Rehydion in our vet practice for approximately two years and we mainly recommend that farmers use it in cattle, but our clients also use it in lambs and kids. We get a lot of positive feedback from farmers on Rehydion, as they feel that it is effective and convenient to use, which aids compliance, and it can be given with milk, which is essential for maintaining a positive energy status."
For further information on the ‘Making Milk Matter Against Scour’ initiative visit www.makingmilkmatter.co.uk, contact your local Ceva Account Manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
References
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Animalcare Ltd has launched Tilmodil (tilmicosin 300mg/ml solution for injection), a semi-synthetic macrolide antibiotic licensed for pneumonia in cattle and sheep, foul in the foot in cattle, and footrot and mastitis in sheep.
According to the company, Tilmicosin is fast-acting1, long-acting2 and highly effective against the major Gram-ve bovine respiratory pathogens.2,3 In addition, the company says tissue penetration is excellent.1 In calves a single SC injection at 10mg/kg bw results in lung concentrations exceeding the MIC90 of Mannheimia haemolytica for 72 hours.2
Animalcare says that pooled data from greater than 6000 cattle has confirmed the effectiveness of tilmicosin in the treatment of bovine respiratory disease (BRD) in well-controlled, randomised field studies. Tilmodil treatment has been proven equally effective compared to antibiotics, such as florfenicol, marbofloxacin and danofloxacin.
A recent report by the Farm Animal Welfare Council estimates that three million of the national sheep flock are lame at any one time. It is estimated that footrot is responsible for greater than 90% of lameness and is present in 97% of flocks. Tilmicosin has good activity against the key Gram-ve pathogens2 and has been successfully used in the treatment of footrot.4
Tilmodil has been developed for animal use only and is administered by veterinary surgeons only. Dosage is 1ml per 30kg bw for respiratory disease and mastitis in sheep and 0.5ml per 30kg bw for interdigital necrobacillosis (foul in the foot/footrot/bovine pododermatitis).
Tilmodil is administered as a single, low volume subcutaneous (SC) injection dose and presented in 50ml multi-dose vials.
1. Apley M., Antimicrobial therapy of Bovine Respiratory Disease.Veterinary Clinics of North America.Food Animal Practice (1997) 13,3:159-5622. Tilmodil SPC3. Giguere S et al .,Antimicrobial therapy in Veterinary Medicine.4th edition 2006.Chp.12,2014. Winter A., Lameness in sheep. 2. Treatment and control. In Practice (2004),3, 130-139.
The British Veterinary Association (BVA) has launched its new ‘Good Practice Guide to Handling Veterinary Waste’ consisting of a poster and web advice.
Produced in association with the BSAVA and Goat Veterinary Society, and supported by The Environment Agency, the poster, alongside further detailed information on the BVA website, provides practical step-by-step guidance designed to assist veterinary surgeons comply with waste regulations in England and Wales.
BVA President Nick Blayney commended the guide to practices, pointing out that “All businesses have a duty of care to ensure that all waste is stored and disposed of responsibly, that it is only handled or dealt with by those authorised to do so and that appropriate records are kept of all waste that is transferred or received. Under the Hazardous Waste Regulations, all veterinary facilities that produce more than 200 kg of hazardous waste per annum need to register and we realised that this was an area where guidance was needed.”
While the production of the guidance had proved to be “a decidedly complicated and time-consuming exercise, we are” said Mr Blayney “absolutely delighted with the outcome and believe that it will make life considerably easier for the profession.”
With definitions of hazardous, including clinical, waste and non-hazardous waste illustrated simply and clearly, coupled with information on registering of premises, maintaining a waste register and the use of consignment notes the BVA is confident that the guide will prove indispensable.
Woodley Equipment Company has announced that Veterinary Parasep Faecal Filters are now available exclusively from the company.
According to the Woodley, the filters have been developed in conjunction with an independent leading veterinary Institution and offer an improved method of determining Worm Egg Counts (WEC) on cattle, sheep and horses. Flotation methods for WEC can require several Specific Gravity solutions to cover different parasites. The two common flotation methods, ‘Modified McMaster' and ‘Improved Modified McMaster', both use Saturated NaCL and are both catered for with Veterinary Parasep.
Woodley says the key advantages of the new filters are:
For a more information about The Veterinary Parasep please email sales@woodleyequipment.com or call the customer service team on +44 (0) 1204 669033 ~ Option 1.
Alternatively, visit http://www.woodleyequipment.com/.
Biogal has announced the launch of the PCRun Molecular Detection Kit, designed to give PCR results in clinic or in the lab within an hour.
The new kit doesn't require any other equipment, such as a thermocycler.
PCRun is a molecular assay based on the isothermal amplification of part of the HapI gene. The company says it is intended for the qualitative detection of pathogenic species of Leptospires only.
The PCRun has been tested at the OEI Leptospira Reference Laboratory in Ireland, on sample materials including urine and kidney biopsies collected from cows experimentally infected with L. hardjo as well as kidney cells.
According to the company, no false positive results were observed in all 63 samples tested and there was excellent correlation between Real Time PCR and PCRun reactions.
Results of the study and a list of serovars tested with PCRun are available from Biogal. See: http://www.biogal.co.il/products/pcrun
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
Janssen Animal Health is advising vets to be on the look out for coccidiosis as the spring lambing season approaches: cases usually rise in March and peak in April and May.
According to the company, some reports also suggest that the incidence of coccidiosis in calves may apparently increase during the grazing months. However, vets are reporting that interpretation of laboratory tests used to confirm diagnosis, such as oocyst count, can be problematic due to the ubiquitous nature of the Eimeria parasite in the UK.
Young animals may be infected by oocysts shed by asymptomatic carriers or infected older cohort animals. Low levels of challenge can help young animals develop immunity but exposure to high oocyst numbers, particularly in combination with stress can lead to clinical and subclinical forms of the disease. Diagnosis can be problematic, particularly in subclinical cases of disease where failure to gain weight is the main presenting sign and in clinical cases the differential diagnoses include all causes of scour in young animals.
Janssen Animal Health has suggested a few indicators that may be useful in identifying cases of coccidiosis. The Vecoxan Coccidiosis Survey in 2008 and 2009 asked farmers about their experiences of coccidiosis and identified that bad weather was a major trigger particularly in lambs; while castration and weaning were also factors in calves. As the parasite life cycle is 21 days, vets should be alert to disease 2-3 weeks after a stressor event.
The company has also suggested a few guidelines to aid interpretation of laboratory results:
Janssen says Vecoxan (diclazuril) does not interfere with the development of immunity and kills all stages of the parasite in the host.
The webinar is being hosted by Dr William Ingham Farrow from Poultry Health Services (PHS), part of the VetPartners group.
William said: “Having worked with a wide variety of different avian species and management systems for over 10 years, I’m delighted to be sharing my experience.
"I hope to bring plenty of useful insight to help young vets gain confidence in this area.
“In this session, I’m aiming to provide advice for first-opinion vets working with both individual hens and backyard flocks.
“I hope to show that you don't need specialist equipment or medication to offer veterinary care for these often overlooked clients, and to signpost the additional help available in more complex cases."
The webinar is part of the Farm Animal Veterinary Society's Car Pool Cases series, which will also cover antibiotic selection (June 25th), camelid care (August 20th), downer cows (October 22nd), youngstock (November 19th) and beef fertility (December 10th).
https://www.eventbrite.co.uk/e/carpool-cases-practical-pointers-from-front-line-farm-vets-tickets-640902997117
To submit questions ahead of the Carpool sessions, email: farmsupport@vetpartners.co.uk
www.favs.org.uk
Charcovet Gel contains 30g of activated charcoal in a 60ml syringe.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare said: “In young animals with digestive disturbances, Charcovet Gel uses the adsorbent properties of activated charcoal to support the gut in a return to normal function.
"The value of using activated charcoal in cases of digestive upset in young animals has long been recognised, but the difficulty and mess involved in mixing such a fine dry powder in water presented considerable usability issues.
"With Charcovet Gel, the appropriate volume of activated charcoal gel is simply selected from the graduated syringe and administered directly into the animal’s mouth.
"Charcovet Gel can be given daily as needed to support the animal during the period of digestive upset.”
Each box of Charcovet Gel contains 12 syringes.
Charcovet Gel is available now from all major veterinary wholesalers, or directly from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: https://www.fortehealthcare.com/product/charcovet-gel
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
The new award, sponsored by Krka UK, will recognise an exceptional farm vet who has been working in the dairy industry for three to five years and who has contributed significantly to the health and wellbeing of herds under their care.
Sarah Tomlinson, veterinary surgeon at Westpoint Farm Vets in Derbyshire, Technical Director of the TB Advisory Service (TBAS) and recipient of the 2020 Dairy Vet of the Year, said: “In recognising achievement among more recently qualified vets with this new award, Krka is giving the boost every young vet needs to shake off the ‘new grad’ title and instead become an ‘high performing’ vet, judged by their industry peers to be one of the best. Many vets can suffer with imposter syndrome so it is important that we accept positive acknowledgement of our work and our everyday achievements so that we can be rightly proud of what we do.”
More information about the CREAM Awards and the nomination process can be found here: https://www.britishdairying.co.uk/cream-awards-2021/
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
The VMD, which reclassified the product following a request from Zoetis, says that increasing the availability of this anthelmintic should help it to be incorporated into strategic worm control programmes on farms in line with best practice guidance on worm control. This could result in long term health benefits for sheep, for example by reducing the development and spread of anthelmintic resistance, thereby prolonging the effective use of anthelmintics.
However, both the British Veterinary Association and the Sheep Veterinary Society have expressed concerns over the move.
BVA Junior Vice President John Fishwick said: "We know that resistance to anthelmintics is increasing in grazing animals worldwide and needs to be addressed to avoid a potentially disastrous situation of being unable to tackle parasites. The reclassification of Startect Dual Active from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is posing a serious threat to animal health, welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in Group 4 as a result.
"BVA believes that the prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis. The drugs are best used as part of a flock health plan drawn up by farmers in conjunction with their vet in order to protect animal health and welfare and safeguard the efficacy of these products for the future."
Sheep Veterinary Society President Kathryn Dun said: "Group 4 anthelmintics should be used only as part of a careful designed strategy for the individual farm and it is imperative that this strategy is worked out with a vet and is part of a flock health plan for that farm. The products need to be used, in the correct way, to help prolong the life of our other anthelmintics.
"We are unlikely to have any further new groups of anthelmintics in the foreseeable future, so education of those buying and selling these products is crucial to ensure the longevity of the effective action of them against sheep parasites."
Further information on BVA's policy on anthelmintics can be found here: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics
Bimeda has announced the launch of a new teat seal which the company claims offers a significant return on investment and an opportunity for veterinary surgeons to prompt farmers to re-evaluate their dry cow therapy and mastitis control.
Bimeda's vet and head of technical services, Padraig Hyland MVB said: "Boviseal is proven to dramatically reduce mastitis in the 100 days post calving¹. Adding competition to the market will encourage farmers to re-assess their dry cow and mastitis strategies.
"The UK launch of Boviseal is a great opportunity for vets to raise the issue of the damage and cost of mastitis, and the potential savings by the correct use of a seal. Boviseal is the number one selling teat seal in the Republic of Ireland, with 2/3 of the Irish dairy cows sealed annually²."
Padraig says the evidence of the value from combined sealing and antibiotic therapy is all too clear when it comes to dry cow therapy. He cites a case study at Waterwheel Farm in Donegal, Ireland which delivered a 300% return on investment: "Combined therapy might sound costly but this two year study saw annual mastitis cases fall dramatically, from 26 per 100 cows to 9 per 100³.
"Defra figures indicate that mastitis is the most costly disease problem that UK dairy farmers face, with a typical case costing £175.00 4. When you compare that against the cost of treatment for the herd, there's no real counter argument in my opinion."
Boviseal contains 65% Bismuth Subnitrate. Padraig says the effectiveness of teat sealing is proven but correct administration is key: "It is important to note that the conventional practice of massaging into the udder after infusion is not employed - the teat seal must stay in the teat canal."
For details on best application practices, the company has developed a website, www.boviseal.co.uk with a video demonstration for correct infusion.
For further information, visit the website or contact Bimeda on 01248 725400.
The trial, which was conducted by a UK-French team of researchers from PBD Biotech and Biosellal, is being presented at the European Association of Veterinary Laboratory Diagnosticians (EAVLD) Congress in Brussels today.
Current tests only allow the reliable detection of Mycobacterium avium subspecies paratuberculosis (MAP) from 18-24 month calves and are unable to distinguish between active and passive infection.
For the 16-month trial, calves from three different herds and born from MAP-positive and MAP-negative cows were tested monthly using PBD Biotech’s Actiphage Rapid kit and Biosellal’s Bio-T kit MAP PCR on blood samples, and the same PCR on faeces.
Researchers say the trial proves that early detection of live MAP infection is possible, and paves the way for improved Johne’s disease monitoring and control measures on farms.
Co-Author Dr Ben Swift, Research Fellow in Antimicrobial Resistance at the Royal Veterinary College and R&D Director at PBD Biotech, said: "Young animals are highly susceptible to infection and being able to identify Johne’s disease at this early stage is key to controlling disease spread.
The trial showed that the sensitivity and specificity of Actiphage enables detection of lower levels of MAP than the current culture methods, and provides results in 6 hours rather than weeks."
The Actiphage Rapid technology used in the trial identified live MAP infection at least 4 weeks’ earlier than the faecal PCR in 75% of cases: in one case, the new diagnostic detected MAP in the blood of a one-day old calf born from a MAP-positive cow.
Claire Pelletier, Directrice Générale of BioDev, consultant to Biosellal, will be presenting findings from the trial, which also showed the transient nature of the infection. She said: "The study showed that two calves, identified as MAP-positive by Actiphage-PCR on blood during the first monthly sampling didn’t shed MAP into their faeces until 10 and 11 months. This emphasises that early detection provides a short window of time that allow for control of the disease."
Other international trials using Actiphage are underway to investigate the presence of MAP in milk.
The test, which enables the rapid identification of cattle infected with Mycobacteria, was first developed by Dr Swift as part of his PhD studies at the University of Nottingham. Since joining the RVC, he has continued to evolve the technology working alongside academics at his former university.
Dr Swift and Dr Rees were presented with the award by HRH the Princess Royal.
The Royal Dairy Innovation Award recognises research and development in the field of dairy farming and is awarded for the most practical, relevant product or service which is, or likely to be the most significant innovation for the future.
The RVC says the test is able to detect mycobacteria in the blood and milk of cattle within six hours using a bacteriophage-based technique. As a result, cattle affected by Mycobacterium bovis, the bacteria that causes bovine TB, can be diagnosed for the disease more quickly, allowing for more effective disease management in herds.
Additionally, the test has been used to effectively detect Johne’s Disease – another endemic illness that affects dairy cattle – in new born calves for the first time. By being able to catch the disease at an early stage, this test can help further with controlling infections in dairy herds.
The test is now licenced to spin-out company, PBD Biotech Ltd and marketed as Actiphage. It can also be used as a highly sensitive quality assurance test in milk and dairy products.
Dr Swift, who is a Research Fellow in antimicrobial resistance, said: "It is really exciting to be recognised with this award. Translating technology from the bench to be used in real-world scenarios is a great thing and really shows the impact of our research. Hopefully this will help manage two extremely difficult diseases in the UK and worldwide."
Photo: Benjamin Swift (RVC), Dr Cath Rees (University of Nottingham), Princess Anne and Dr Berwyn Clarke (PBD Biotech).
The Envirobed cubicle bedding study found that cow comfort is farmers' number one priority, rated 'very important' by 89% and 'quite important' by 9%. A close second, scoring 81% 'very important' and 13% 'quite important', was reducing mastitis bugs. Allied to this, number three was high absorbency bedding, scoring 71% and 16% respectively. Farmers taking part used a variety of different bedding materials.
The importance of reducing humidity in cow housing was also well recognised. To improve ventilation, ridge tiles have been removed by 38% and fans installed by 9% of farmers. Another 18% and 10% respectively are considering these two options.
Sally Russell from Envirosystems points out that keeping cows clean and comfortable doesn't need be compromised by this winter's shortage and high cost of bedding straw: "Although this is driving up the cost of sawdust and some other materials, there are exceptions.
"For example, some farmers with beef cattle and dairy replacements in straw yards are using a deep bed of Envirobed Original, made from 100% dried recycled paper. Others place a 15cm layer on the floor and top it off with straw.
"For cubicles, the usual material of choice is EnviroBed Premium, a blend of dried paper and kiln dried virgin wood sawdust. Per cubicle, the recommended daily quantity and cost are just 1kg at less than 10p."
Envirosystems says both materials are 95% dry matter and mildly alkaline 7.4 pH, helping create a dry and comfortable area that is unfavourable to disease organisms and fly eggs. They are also biodegradeable and compatible with all manure systems.
Envirosystems has given the findings of its research to farming unions, Dairy UK and AHDB Dairy with permission to use the data if it helps them promote an accurate and caring image of farming, contrary to misleading propaganda put about all too often by the industry's numerous critics.
Photo: Comfy Cow, copyright Ivor Davey
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
MSD has announced that the broad-spectrum clostridial disease vaccine for sheep and cattle, Bravoxin 10, is now available in a new 6 x 100ml farm vaccination pack. The pack contains enough vaccine for 600 sheep or 300 cattle boosters.
Buyers of the new farm pack will also get a free vaccine applicator worth £20. The new Bravoxin 10 applicator benefits from the sterimatic system, which protects and sterilises the vaccination needle with each injection. MSD says it can also be placed down between doses without risk of needle damage, self-injection or needing to remove the vaccine bottle.
Bravoxin 10 protects both cattle and sheep from clostridial diseases like blackleg and black disease, as well as other conditions caused by clostridial bacteria that usually kill the animal once infection has become established. The vaccine protects against disease caused by the 10 main clostridial bacteria; C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.